Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 6-(2-(4-(bis(4-fluorophenyl)methylene)-1-piperidinyl)ethyl)-7-methyl-5h-thiazolo(3,2-a)pyrimidin-5-one
2. R 55667
3. R-55667
4. R55667
5. Ritanserin Hydrochloride
6. Ritanserin Tartrate
1. 87051-43-2
2. Tiserton
3. Ritanserina
4. Ritanserine
5. Ritanserinum
6. R-55667
7. R 55,667
8. 6-(2-(4-(bis(4-fluorophenyl)methylene)piperidin-1-yl)ethyl)-7-methyl-5h-thiazolo[3,2-a]pyrimidin-5-one
9. 6-[2-[4-[bis(4-fluorophenyl)methylidene]piperidin-1-yl]ethyl]-7-methyl-[1,3]thiazolo[3,2-a]pyrimidin-5-one
10. Mfcd00069341
11. 6-(2-(4-(bis(p-fluorophenyl)methylene)-piperidino)ethyl)-7-methyl-5h-thiazolo-(3,2-a)pyrimidin-5-one
12. Nsc-758470
13. Mls000069360
14. Chembl267777
15. 6-(2-(4-(bis(4-fluorophenyl)methylene)piperidin-1-yl)-ethyl)-7-methyl-5h-thiazolo[3,2-a]pyrimidin-5-one
16. 6-(2-{4-[bis(4-fluorophenyl)methylidene]piperidin-1-yl}ethyl)-7-methyl-5h-[1,3]thiazolo[3,2-a]pyrimidin-5-one
17. Chebi:64195
18. 145tfv465s
19. Ncgc00015877-06
20. Smr000058511
21. Dsstox_cid_22594
22. Dsstox_rid_80055
23. Dsstox_gsid_42594
24. 5h-thiazolo(3,2-a)pyrimidin-5-one, 6-(2-(4-bis(4-fluorophenyl)methylene)-1-piperidinyl)ethyl)-7-methyl-
25. 6-[2-[4-(bis(4-fluorophenyl)methylene]-1-piperidinyl]ethyl]-7-methyl-5h-thiazolo[3,2-a]pyrimidin-5-one
26. 6-[2-[4-[bis(4-fluorophenyl)methylidene]piperidin-1-yl]ethyl]-7-methyl-[1,3]thiazolo[2,3-b]pyrimidin-5-one
27. Ritanserine [french]
28. Ritanserinum [latin]
29. Ritanserina [spanish]
30. 6-[2-[4-[bis(4-fluorophenyl)methylene]-1-piperidinyl]ethyl]-7-methyl-5h-thiazolo[3,2-a]pyrimidin-5-one
31. Cas-87051-43-2
32. Sr-01000000024
33. Ritanserin [usan:inn:ban]
34. Unii-145tfv465s
35. Ritanserin, Powder
36. Tiserton (tn)
37. 5h-thiazolo[3,2-a]pyrimidin-5-one, 6-[2-[4-bis(4-fluorophenyl)methylene]-1-piperidinyl]ethyl]-7-methyl-
38. 6-[2-[4-[bis(p-fluorophenyl)methylene]-piperidino]ethyl]-7-methyl-5h-thiazolo-[3,2-a]pyrimidin-5-one
39. Spectrum_001830
40. Ritanserin [mi]
41. Lopac-r-103
42. Ritanserin [inn]
43. Opera_id_1609
44. Ritanserin (usan/inn)
45. Spectrum2_001560
46. Spectrum3_001023
47. Spectrum5_001504
48. Ritanserin [usan]
49. Ritanserin [vandf]
50. Gtpl97
51. Cid_5074
52. Ritanserin [mart.]
53. Ritanserin [who-dd]
54. Lopac0_001083
55. Regid_for_cid_5074
56. Schembl49227
57. Bspbio_002805
58. Kbioss_002335
59. Mls001148629
60. Divk1c_000192
61. Spbio_001440
62. Dtxsid9042594
63. Hms500j14
64. Kbio1_000192
65. Kbio2_002332
66. Kbio2_004900
67. Kbio2_007468
68. Kbio3_002025
69. Ninds_000192
70. Hms2093e19
71. Hms2233m22
72. Hms3263i08
73. Hms3268o04
74. Hms3373o19
75. Hms3412n14
76. Hms3676n14
77. Pharmakon1600-01503421
78. Zinc538314
79. Bcp13728
80. Tox21_110251
81. Tox21_501083
82. Bdbm50001775
83. Ccg-39338
84. Nsc758470
85. Nsc805597
86. Akos015909799
87. Tox21_110251_1
88. Db12693
89. Lp01083
90. Nsc 758470
91. Nsc-805597
92. Sdccgsbi-0051053.p004
93. 6-[2-[4-[bis(4-fluorophenyl)methylidene]piperidin-1-yl]ethyl]-7-methyl-[1,3]thia
94. Idi1_000192
95. Ncgc00015877-01
96. Ncgc00015877-02
97. Ncgc00015877-03
98. Ncgc00015877-04
99. Ncgc00015877-05
100. Ncgc00015877-07
101. Ncgc00015877-08
102. Ncgc00015877-09
103. Ncgc00015877-11
104. Ncgc00015877-15
105. Ncgc00022447-03
106. Ncgc00022447-04
107. Ncgc00022447-05
108. Ncgc00178460-01
109. Ncgc00261768-01
110. 6-[2-[4-[bis(4-fluorophenyl)methylene]-1-piperidyl]ethyl]-7-methyl-thiazolo[3,2-a]pyrimidin-5-one
111. Ac-30888
112. Bs-49232
113. Hy-10791
114. Sy274388
115. Sbi-0051053.p003
116. Db-056967
117. B6898
118. Cs-0002823
119. Eu-0101083
120. Ft-0630948
121. R-103
122. D05738
123. Ab00053288_14
124. 051r432
125. A848404
126. L001003
127. R 55667r 55667
128. Q3937260
129. Sr-01000000024-3
130. Sr-01000000024-4
131. Brd-k40887525-001-02-9
132. Brd-k40887525-001-14-4
133. Ethyl]-7-methyl-5h-thiazolo[3,2-a]pyrimidin-5-one
134. 6-[2-[4-bis(4-fluorophenyl)methylene]-1-piperidinyl]-
135. (+)-6-[2-[4-[bis(4-fluorophenyl)methylene]-1-piperidinyl]ethyl]-7-methyl-5h-thiazolo[3,2-a]pyrimidin-5-one
136. (ritanserin)6-(2-{4-[bis-(4-fluoro-phenyl)-methylene]-piperidin-1-yl}-ethyl)-7-methyl-2,3-dihydro-1h-indolizin-5-one
137. (ritanserin)6-(2-{4-[bis-(4-fluoro-phenyl)-methylene]-piperidin-1-yl}-ethyl)-7-methyl-thiazolo[3,2-a]pyrimidin-5-one
138. 6-(2-(4-[bis(4-fluorophenyl)methylene]-1-piperidinyl)ethyl)-7-methyl-5h-[1,3]thiazolo[3,2-a]pyrimidin-5-one #
139. 6-(2-{4-[bis-(4-fluoro-phenyl)-methylene]-piperidin-1-yl}-ethyl)-7-methyl-8,8a-dihydro-thiazolo[3,2-a]pyrimidin-5-one
140. 6-(2-{4-[bis-(4-fluoro-phenyl)-methylene]-piperidin-1-yl}-ethyl)-7-methyl-thiazolo[3,2-a]pyrimidin-5-one
141. 6-(2-{4-[bis-(4-fluoro-phenyl)-methylene]-piperidin-1-yl}-ethyl)-7-methyl-thiazolo[3,2-a]pyrimidin-5-one (ritanserin)
142. 6-(2-{4-[bis-(4-fluoro-phenyl)-methylene]-piperidin-1-yl}-ethyl)-7-methyl-thiazolo[3,2-a]pyrimidin-5-one(ritanserin)
143. 6-[2-[4-[bis(4-fluorophenyl)-methylene]-1-piperidinyl]ethyl]-7-methyl-5h-thiazolo[3,2-a]-pyrimidin-5-one
144. E2j
| Molecular Weight | 477.6 g/mol |
|---|---|
| Molecular Formula | C27H25F2N3OS |
| XLogP3 | 5.2 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 5 |
| Exact Mass | 477.16863993 g/mol |
| Monoisotopic Mass | 477.16863993 g/mol |
| Topological Polar Surface Area | 61.2 Ų |
| Heavy Atom Count | 34 |
| Formal Charge | 0 |
| Complexity | 877 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Antidepressive Agents, Second-Generation
A structurally and mechanistically diverse group of drugs that are not tricyclics or monoamine oxidase inhibitors. The most clinically important appear to act selectively on serotonergic systems, especially by inhibiting serotonin reuptake. (See all compounds classified as Antidepressive Agents, Second-Generation.)
Antipsychotic Agents
Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. (See all compounds classified as Antipsychotic Agents.)
Anti-Anxiety Agents
Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here. (See all compounds classified as Anti-Anxiety Agents.)
Serotonin Antagonists
Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or SEROTONIN RECEPTOR AGONISTS. (See all compounds classified as Serotonin Antagonists.)
INTERMEDIATES SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
ABOUT THIS PAGE
A Ritanserin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ritanserin, including repackagers and relabelers. The FDA regulates Ritanserin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ritanserin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Ritanserin supplier is an individual or a company that provides Ritanserin active pharmaceutical ingredient (API) or Ritanserin finished formulations upon request. The Ritanserin suppliers may include Ritanserin API manufacturers, exporters, distributors and traders.
click here to find a list of Ritanserin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Ritanserin DMF (Drug Master File) is a document detailing the whole manufacturing process of Ritanserin active pharmaceutical ingredient (API) in detail. Different forms of Ritanserin DMFs exist exist since differing nations have different regulations, such as Ritanserin USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Ritanserin DMF submitted to regulatory agencies in the US is known as a USDMF. Ritanserin USDMF includes data on Ritanserin's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Ritanserin USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Ritanserin suppliers with USDMF on PharmaCompass.
Ritanserin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Ritanserin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Ritanserin GMP manufacturer or Ritanserin GMP API supplier for your needs.
A Ritanserin CoA (Certificate of Analysis) is a formal document that attests to Ritanserin's compliance with Ritanserin specifications and serves as a tool for batch-level quality control.
Ritanserin CoA mostly includes findings from lab analyses of a specific batch. For each Ritanserin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Ritanserin may be tested according to a variety of international standards, such as European Pharmacopoeia (Ritanserin EP), Ritanserin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Ritanserin USP).
LOOKING FOR A SUPPLIER?
